IMVT Earnings Date: Nov 9, 2026 (Estimated) — Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is IMVT's next earnings date?
Immunovant, Inc. (IMVT) is expected to report Q2 2027 earnings on Monday, November 9, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.74 on revenue of $7.1M.
How did IMVT do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q1 2027), Immunovant, Inc. posted EPS of -$0.75 versus the -$0.63 estimate, a miss of 44.2%. Revenue was $0 against a $7.1M estimate. The stock's 1-day post-earnings move was +1.2%.
How much does IMVT stock move after earnings?
IMVT beat EPS estimates in 1 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.9% (up or down) in the day after earnings.
About Immunovant, Inc.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q1 2027 | -0.63 | -0.75 | -44.23% | $0 | ❌ Miss | +1.17% | +8.45% | -0.41% |
| 2026-05-20 | Q4 2026 | -0.62 | -0.73 | -17.74% | $0 | ❌ Miss | +35.26% | +27.08% | +34.42% |
| 2026-02-06 | Q3 2026 | -0.71 | -0.61 | +14.08% | $0 | ✅ Beat | +12.43% | +6.57% | +9.77% |
| 2025-11-10 | Q2 2026 | -0.72 | -0.73 | -1.39% | $0 | ❌ Miss | +0.09% | +1.67% | -2.53% |
| 2025-08-11 | Q1 2026 | -0.68 | -0.71 | -4.41% | $0 | ❌ Miss | -4.53% | -1.55% | +6.08% |
| 2025-02-06 | Q3 2025 | -0.76 | -0.76 | +0.00% | $0 | ➖ Inline | -9.55% | -14.62% | -11.06% |
| 2024-11-07 | Q2 2025 | -0.60 | -0.74 | -23.33% | $0 | ❌ Miss | -4.74% | -8.02% | -8.91% |
| 2024-08-06 | Q1 2025 | -0.53 | -0.60 | -13.21% | $0 | ❌ Miss | -3.12% | +6.97% | +20.72% |
Showing last 8 quarters.